3/22
10:24 pm
mist
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China
Medium
Report
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China
3/20
09:52 am
mist
Milestone Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Milestone Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
3/20
08:24 am
mist
Milestone Pharmaceuticals GAAP EPS of -$0.75, revenue of $1.55M [Seeking Alpha]
Medium
Report
Milestone Pharmaceuticals GAAP EPS of -$0.75, revenue of $1.55M [Seeking Alpha]
3/20
07:56 am
mist
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT [Yahoo! Finance]
3/16
08:23 am
mist
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session [Yahoo! Finance]
3/16
08:13 am
mist
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
Low
Report
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
3/14
02:56 am
mist
Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality [Seeking Alpha]
Low
Report
Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality [Seeking Alpha]
3/12
08:12 am
mist
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 [Yahoo! Finance]
Neutral
Report
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 [Yahoo! Finance]
3/12
08:00 am
mist
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Low
Report
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
2/26
08:34 am
mist
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/26
08:00 am
mist
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Low
Report
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
2/26
06:28 am
mist
Milestone Pharmaceuticals (MIST) was downgraded by Zacks Research from "strong-buy" to "hold".
Neutral
Report
Milestone Pharmaceuticals (MIST) was downgraded by Zacks Research from "strong-buy" to "hold".
2/10
08:00 am
mist
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Low
Report
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
2/3
08:00 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/28
07:29 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/27
08:33 am
mist
Milestone Pharmaceuticals announces U.S. availability of cardamyst [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals announces U.S. availability of cardamyst [Yahoo! Finance]
1/26
08:18 am
mist
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
Medium
Report
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
1/26
08:00 am
mist
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Low
Report
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
1/15
09:56 am
mist
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense [Seeking Alpha]
Low
Report
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense [Seeking Alpha]
1/7
08:51 am
mist
Milestone announces acceptance of MAA by EMA for etripamil nasal spray [Yahoo! Finance]
Medium
Report
Milestone announces acceptance of MAA by EMA for etripamil nasal spray [Yahoo! Finance]
1/6
12:50 pm
mist
Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
1/6
08:00 am
mist
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Neutral
Report
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency